Covaxin Shows Overall Efficacy Of 77.8% Against Symptomatic COVID-19 Cases

Hyderabad-based Bharat Biotech On July 3 published the results of the final analysis of the Phase-3 trial of Covaxin.

The clinical trials as a part of phase III clinical trials involved nearly 25,800 volunteers spanning 25 hospitals across the country. Along with the Indian Council of Medical Research (ICMR), the pharmaceutical company said that the vaccine had an overall efficacy of 77.8% against symptomatic COVID.

According to ANI, Chairman of the Covid working group Dr NK Arora said that the vaccine’s efficacy results will help the vaccine in getting WHO's emergency use approval. If approved, it will also increase the visibility of the country on the world stage.

COVAXIN® Proven SAFE in India's Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V pic.twitter.com/AhnEg56vFN

— BharatBiotech (@BharatBiotech) July 2, 2021

The co-founder of Bharat Biotech Suchitra Ella said in a tweet, "We are proud to put India on the global map with scientific conviction, competence and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy. Thank collaborators & Positive BB teamwork enduring a pandemic".

We are proud to put India on the global map with scientific conviction,competence & commitment. #Covaxin scores #10 world class publications endorsing Innovation, clinical research,data,safety, efficacy. Thanq collaborators & Positive BB teamwork enduring a pandemic 😇👏🏼👍🏼💉🇮🇳🙏🏼 https://t.co/c5f43WOAbQ

— suchitra ella (@SuchitraElla) July 2, 2021

Earlier, the Phase-3 trial results of the AstraZeneca (Covishield) vaccine were published in Lancet in January demonstrated overall efficacy of 70.4%.

However, the Covaxin study published recently has to be peer-reviewed and appears on a pre-print server. The two-dose vaccine offers "65.2 per cent protection" against the rapidly emerging Delta variant. The company said Covaxin was found to be "93.4 per cent effective" against severe symptomatic COVID-19.

As per the pre-print, the vaccine was 67.8% effective on people who were 60 years and older and 79.4% effective in younger people.

In a statement, the company said that the safety analysis demonstrated adverse events reported “were similar to placebo” with “12% of subjects” experiencing common side-effects and “less than 0.5% of subjects” felt severe adverse events.

Meanwhile, Covid-19 cases dipped again on Saturday as India recorded 44,111 fresh infections. As per the Union health ministry's data, the latest cases have taken the country's cumulative tally past 30.5 million. Currently, the recovery rate in the nation stands at 97.01% on July 3.